We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Edesa Biotech is set to continue Phase II/III clinical study of its drug candidate, EB05, to treat patients hospitalised with Covid-19 on receiving an independent Data and Safety Monitoring Board’s (DSMB) recommendation.
Biopharma firm Edesa Biotech has received clearance from the US Food and Drug Administration (FDA) to initiate the Phase II part of Phase II / III clinical trial of its investigational drug EB05 to treat hospitalised patients with Covid-19.